Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | PARP1 | P09874 | 4/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 5/20 | 0.33 |
| ▸ | CASP7 | P55210 | 2/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | FER | P16591 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12097976 | 0.81 | THRB (0.43) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL5970012 | 0.81 | GSK3B (0.50) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL4431549 | 0.80 | GSK3B (0.39) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL8385957 | 0.78 | ALDH1A1 (0.38) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL7300058 | 0.78 | ALDH1A1 (0.38) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL6470239 | 0.78 | GSK3B (0.43) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL10719295 | 0.78 | TYMS (0.44) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL6509073 | 0.77 | ALDH1A1 (0.36) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL30225439 | 0.77 | KDM4E (0.39) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL170914 | 0.76 | GABRA1 (0.49) | KDM4EALDH1A1GAAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3023495-B1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-1589999-B1 | POLYVINYLETHERS FOR DELIVERY OF POLYNUCLEOTIDES TO MAMMALIAN CELLS | ARROWHEAD PHARMACEUTICALS INC (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10022456-B2 | Reversibly masked polymers | Arrowhead Pharmaceuticals, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9796756-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-07-20 | — | — | US | disclosed |
| EP-3192800-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2652134-B1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2017-01-26 | — | — | US | disclosed |
| WO-1995013861-A1 | A METHOD FOR SEPARATION AND SYNTHETIC POLYMERS THAT CAN BE USED AS SEPARATION MEDIA IN THE METHOD | PHARMACIA BIOTECH AB (SE) | 1995-05-26 | — | — | WO | disclosed |
| EP-0643760-A1 | POLY(VINYL ETHER) AMINOCARBAMATES AND FUEL COMPOSITIONS CONTAINING THE SAME | CHEVRON CHEMICAL COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0643759-A1 | POLY(ALKYLENE ETHER) HYDROXY (OXYPROPYLENE) AMINES AND FUEL COMPOSITIONS CONTAINING THE SAME | CHEVRON CHEMICAL COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0643758-A1 | POLY(VINYL ETHER) AMINES AND FUEL COMPOSITIONS CONTAINING THE SAME | CHEVRON CHEMICAL COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1994022985-A1 | POLY(ALKYLENE ETHER) HYDROXY (OXYPROPYLENE) AMINES AND FUEL COMPOSITIONS CONTAINING THE SAME | CHEVRON RESEARCH AND TECHNOLOGY COMPANY, A DIVISION OF CHEVRON U.S.A. INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022986-A1 | POLY(VINYL ETHER) AMINOCARBAMATES AND FUEL COMPOSITIONS CONTAINING THE SAME | CHEVRON RESEARCH AND TECHNOLOGY COMPANY, A DIVISION OF CHEVRON U.S.A. INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022987-A1 | POLY(VINYL ETHER) AMINES AND FUEL COMPOSITIONS CONTAINING THE SAME | CHEVRON RESEARCH AND TECHNOLOGY COMPANY, A DIVISION OF CHEVRON U.S.A. INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5306314-A | Fuel additive; antideposit agents | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| US-5306315-A | Fuel additive; antideposit agents; fuel concentrate | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| US-5306316-A | Poly(alkylene ether) amines having a hydroxy(oxypropylene) connecting group | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | KDM4E 1014/4885ALDH1A1 4683/4885GAA 453/4885 |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | PHAX, RNASE1, SNRPE | KDM4E 4413/4885ALDH1A1 4718/4885GAA 2339/4885 |
| US-10022456-B2 | Reversibly masked polymers | CD47, MSN, EPCAM | KDM4E 3697/4885ALDH1A1 4496/4885GAA 325/4885 |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | KDM4E 4413/4885ALDH1A1 4718/4885GAA 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.